Amgen (HKSE:04332) Cyclically Adjusted Book per Share: HK$118.73 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:04332 Amgen Inc HKSE:04332
79 GF Score
Price HK$1,761.00
GF Value HK$1,463.66
! 8 Warning Signs
View Full Analysis

What is Amgen Cyclically Adjusted Book per Share?

Amgen HKSE:04332 79 Cyclically Adjusted Book per Share is HK$118.73 as of Jun. 2026. GuruFocus rates HKSE:04332 with a GF Score™ of 79/100 and a GF Value™ of HK$1,463.66. The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Amgen's adjusted book value per share for the three months ended in Jun. 2026 was HK$169.454. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is HK$118.73 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Amgen's average Cyclically Adjusted Book Growth Rate was -10.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -7.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -4.90% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -0.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Amgen was 38.80% per year. The lowest was -7.60% per year. And the median was 12.60% per year.

As of today (2026-08-23), Amgen's current stock price is HK$1761.00. Amgen's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was HK$118.73. Amgen's Cyclically Adjusted PB Ratio of today is 14.83.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Amgen was 18.90. The lowest was 4.86. And the median was 7.51.


Amgen  (HKSE:04332) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Amgen's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1761.00/118.73
=14.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Amgen was 18.90. The lowest was 4.86. And the median was 7.51.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Amgen Cyclically Adjusted Book per Share Related Terms


Amgen Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Amgen's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen Cyclically Adjusted Book per Share Chart

Amgen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 258.71 216.60 188.46 191.79 137.12

Amgen Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 171.21 165.20 137.12 125.30 118.73

HKSE:04332 vs GILD, PFE, BMY: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - General subindustry, Amgen's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amgen Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Amgen's Cyclically Adjusted PB Ratio falls into.


HKSE:04332
79GF Score
Amgen Inc HKSE:04332
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amgen Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Amgen's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=169.454/333.9520*333.9520
=169.454

Current CPI (Jun. 2026) = 333.9520.

Amgen Quarterly Data

Book Value per Share CPI Adj_Book
201609 320.472 241.428 443.289
201612 314.076 241.432 434.434
201703 323.218 243.801 442.735
201706 338.553 244.955 461.556
201709 346.539 246.819 468.876
201712 273.059 246.524 369.897
201803 183.795 249.554 245.954
201806 180.266 251.989 238.900
201809 175.557 252.439 232.245
201812 155.245 251.233 206.360
201903 138.383 254.202 181.797
201906 140.299 256.143 182.918
201909 143.598 256.759 186.770
201912 127.651 256.974 165.890
202003 125.258 258.115 162.060
202006 140.874 257.797 182.489
202009 145.557 260.280 186.757
202012 126.124 260.474 161.703
202103 125.985 264.877 158.840
202106 112.378 271.696 138.128
202109 113.158 274.310 137.761
202112 93.594 278.802 112.108
202203 13.414 287.504 15.581
202206 35.492 296.311 40.001
202209 53.747 296.808 60.473
202212 53.375 296.797 60.057
202303 78.560 301.836 86.919
202306 99.300 305.109 108.687
202309 112.007 307.789 121.528
202312 90.905 306.746 98.968
202403 73.308 312.332 78.382
202406 86.172 314.175 91.596
202409 109.103 315.301 115.557
202412 85.073 315.605 90.019
202503 89.734 319.799 93.705
202506 108.303 322.561 112.128
202509 139.055 324.800 142.973
202512 125.030 324.054 128.849
202603 133.275 330.213 134.784
202606 169.454 333.952 169.454

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of HK$118.73 mean?
Amgen (HKSE:04332) has a Cyclically Adjusted Book per Share of HK$118.73 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Amgen and its competitors.
Is Amgen's Cyclically Adjusted Book per Share too high?
Amgen's current Cyclically Adjusted Book per Share is HK$118.73. Overall, Amgen has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Amgen's Cyclically Adjusted Book per Share compare to GILD and PFE?
Amgen's Cyclically Adjusted Book per Share of HK$118.73 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Amgen and its competitors. Amgen's current Cyclically Adjusted Book per Share is HK$118.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Amgen (HKSE:04332) has a current Cyclically Adjusted Book per Share of HK$118.73. The stock's GF Value™ is HK$1,463.66, compared to a current price of HK$1,761.00 — trading 20.3% above its estimated fair value. The current Cyclically Adjusted Book per Share is HK$118.73. Amgen's overall GF Score™ is 79/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Amgen (HKSE:04332), the current Cyclically Adjusted Book per Share is HK$118.73 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amgen (HKSE:04332) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be overvalued. The current stock price of HK$1,761.00 is trading 20.3% above its estimated GF Value™ of HK$1,463.66.

Key valuation signals for HKSE:04332:

  • Cyclically Adjusted Book per Share: HK$118.73
  • GF Value™: HK$1,463.66 vs. price of HK$1,761.00 (20.3% above fair value)
  • GF Score™: 79/100 with 8 warning signs

No single metric tells the full story. See the HKSE:04332 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
79GF Score

Get the complete analysis for HKSE:04332

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1,761.00
Price
HK$1,463.66
GF Value